A promoter variant of the APOA5 gene increases atherogenic LDL levels and arterial stiffness in hypertriglyceridemic patients
Table 2
Associations of the APOA5 -1131T>C polymorphism with apoA5 levels and serum lipid profiles in normotriglyceridemic controls and hypertriglyceridemic patients.